Join the club for FREE to access the whole archive and other member benefits.

Kris Barnes

PhD, CEO and Founder of Lento Bio

Dr. Barnes’ principle professional interest has long been to develop therapies to protect valuable human lives against aging and age-related disease. He earned his BS in Biology from SUNY Oswego and his PhD in neuroscience from Weill Cornell Medicine, where he published his thesis work on neurodevelopment in eLife while also gaining exposure across multiple therapeutic areas including ophthalmology drug development.

He served as VP of the Tri-Institutional consulting club and subsequently joined Lifescience Dynamics, where he provided competitive intelligence consulting services for established pharmaceutical and biotechnology companies in indications across immunology, ophthalmology, rare blood disorders, and cardiology.

He founded Lento Bio with the goal of developing novel treatments for chronic diseases.


Visit website: https://lentobio.com/a5213-home/team-3/kris-2/

 kris-barnes-phd-7912a734

See also: Company Lento Bio - Preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease

Details last updated 29-Jun-2022

Kris Barnes News

FSU researcher and Lento Bio collaborate to treat age-related vision loss

FSU researcher and Lento Bio collaborate to treat age-related vision loss

Florida State University - 17-May-2023

Aims to cure presbyopia by restoring elasticity of the lens & inhibiting ageing process

Lento Bio raised $680,000 aiming to restore near vision in presbyopia patients

Lento Bio raised $680,000 aiming to restore near vision in presbyopia patients

Lento Bio - 06-Sep-2022

Ichor Life Sciences leads the investment to advance anti-glycation therapies

Lento bio to launch anti-glycation drugs targeting anti-aging and presbyopia

Lento bio to launch anti-glycation drugs targeting anti-aging and presbyopia

Ichor Therapeutics - 06-Jun-2022

Lento Bio research into molecular aging damage by accelerating clinical assets